Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > The number of Board Members

<< Previous

Bullboard Posts

Next >>

Comment by Hand2Handon Apr 09, 2023 8:43pm

125 Views

Post# 35386089

RE:RE:RE:RE:The number of Board Members

No the ball is in BP's court. Without BP.s approval to use their Check Point there will be no Phase 3. And it can only be Merck or Roche. If another pharma wants to use their check point then the whole testing has to start from scratch. And yes Pfizer is definitely out since they back all the rights of Bavencio back to Merck.

<< Previous

Bullboard Posts

Next >>

Umicore hits pause on Canadian battery materials plant construction